teclistamab,daratumumab,talquetamab,tocilizumab
genmab,janssen,Roche,JW Pharma
['mmsm', 'toci']
aa4: - tt showed crs grade 1/2 in 74%, time to onset 2 days, duration was 2 days, with 21% use toci. icans g3: reported in 3% #mmsm #myeloma #medtiwtter #usmirc #asco23 
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter